公开(公告)号：WO2019067413A1

公开(公告)日：2019-04-04

申请号：PCT/US2018/052580

申请日：2018-09-25

Applicant: ZOGENIX INTERNATIONAL LIMITED ,  FARFEL, Gail ,  LOCK, Michael ,  GALER, Bradley S. ,  MORRISON, Glenn ,  BOYD, Brooks M.

Inventor： FARFEL, Gail ,  LOCK, Michael ,  GALER, Bradley S. ,  MORRISON, Glenn ,  BOYD, Brooks M.

IPC: A61K31/137 ,  A61P25/08 ,  A61K45/06

CPC classification number: A61P25/08 ,  A61K31/137 ,  A61K45/06 ,  A61K2300/00

Abstract: A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.